Trodelvy is an effective new drug that could give certain women living with incurable triple negative secondary breast cancer the hope of more time. More time to enjoy with loved ones and to do things that matter most to them.

In April, the drug was provisionally rejected for use on the NHS in England. However, thanks to Breast Cancer Now supporters who backed our Time For Trodelvy campaign , the decision was reversed in July and Trodelvy will now finally be available to the women who could benefit from it.

What we achieved

When Trodelvy was rejected, we launched an open letter calling on pharmaceutical company, Gilead, NICE and NHS England to find a solution to make Trodelvy available to the women who need it. Over 114,366 people added their name – creating pressure that was a critical factor in reversing the provisional decision .

We want to say a massive thank you to everybody who added their name and helped us send the strongest message possible that this drug needed to be made routinely available on the NHS.

Trodelvy is one of the few targeted drugs available to people in my situation, with my type of aggressive cancer. So, it's a huge relief to know it will be available on the NHS when I need it. 'When you’re living with triple negative secondary breast cancer, having a new treatment line that could give you more time provides you with hope and a chance to make more memories with those you love. I want to say a huge thank you to everyone who signed the open letter, I cannot express my gratitude enough to those who supported the campaign


Frequently asked questions